EUVIMEDEUVIMED entdecken
Open Access

OPRM1 rs1799971 Polymorphism Predicts Differential Response to Extended-Release Naltrexone in Alcohol Use Disorder: The Interplay of Genetics and Motivation

Valentin Skryabin, Sergei Miroshkin, Anton Masyakin, Sergei Pozdniakov, Valentina Ivanchenko, Valery Shipitsin

Psychopharmacology Bulletin · 2025

DOI: 10.64719/pb.4546 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Psychopharmacology Bulletin, 2025. Verfasst von Valentin Skryabin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Skryabin, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia. Hauptthemen laut MEDLINE: Naltrexone, Receptors, Opioid, mu, Alcoholism, Motivation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alcohol use disorder (AUD) remains a major contributor to the global burden of disease. Extended-release naltrexone (XR-NTX), a μ-opioid receptor antagonist, is a key pharmacological option for maintaining abstinence, though individual treatment response varies substantially. Genetic variability in the μ-opioid receptor gene (OPRM1), particularly rs1799971, may underpin this heterogeneity. Study objective was to evaluate the association between OPRM1 rs1799971 polymorphism and clinical outcomes of XR-NTX therapy in patients with AUD while examining interactions with motivational profiles. In this prospective study, 100 patients with AUD in remission received six monthly intramuscular injections of XR-NTX (380 mg). Genotyping for OPRM1 rs1799971 was performed using real-time allele-specific PCR. Primary outcomes included craving dynamics (PACS), relapse rates, abstinence duration, and treatment adherence over 180 days. Motivation was assessed through structured interviews. The A/A genotype was associated with longer abstinence (150.6 ± 36.2 days), lower relapse rates (29.2%), greater craving reduction, and higher treatment completion (86.2%) compared to A/G and G/G (A/A vs. A/G: p = 0.005; A/A vs. G/G: p = 0.021). The G allele significantly increased relapse risk (OR = 2.93; 95% CI: 1.48−5.79). Intrinsic motivation was associated with better outcomes. A significant genotype-motivation interaction was observed (p = 0.038). No genotype-related differences in adverse event frequency were observed. OPRM1 rs1799971 polymorphism significantly influences the efficacy of XR-NTX in AUD. Carriers of the A/A genotype derive greater therapeutic benefit, while G allele carriers may require intensified clinical support. Pre-therapeutic OPRM1 genotyping could optimize XR-NTX personalization, with G-allele carriers warranting intensified psychosocial support. Psychopharmacology Bulletin. 2025;55(4):68–78.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NaltrexoneReceptors, Opioid, muAlcoholismMotivationNarcotic AntagonistsHumansMaleFemaleMiddle AgedAdultDelayed-Action PreparationsProspective StudiesGenotypeCravingTreatment OutcomePolymorphism, Single Nucleotide

Stichwörter der Autor:innen

AUDOPRM1 polymorphismextended-release naltrexonepersonalized medicinepharmacogeneticsrs1799971

Substanzen

NaltrexoneReceptors, Opioid, muOPRM1 protein, humanDelayed-Action PreparationsNarcotic Antagonists

Autor:innen und Institutionen

  • Skryabin, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.
  • Miroshkin, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.
  • Masyakin, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.
  • Pozdniakov, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.
  • Ivanchenko, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.
  • Shipitsin, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.

Zitieren

APA

Skryabin, V., Miroshkin, S., Masyakin, A., Pozdniakov, S., Ivanchenko, V., & Shipitsin, V. (2025). OPRM1 rs1799971 Polymorphism Predicts Differential Response to Extended-Release Naltrexone in Alcohol Use Disorder: The Interplay of Genetics and Motivation. Psychopharmacology Bulletin. https://doi.org/10.64719/pb.4546

Vancouver

Skryabin V, Miroshkin S, Masyakin A, Pozdniakov S, Ivanchenko V, Shipitsin V. OPRM1 rs1799971 Polymorphism Predicts Differential Response to Extended-Release Naltrexone in Alcohol Use Disorder: The Interplay of Genetics and Motivation. Psychopharmacology Bulletin. 2025. doi:10.64719/pb.4546

BibTeX
@article{Skryabin2025,
  author = {Skryabin, Valentin and Miroshkin, Sergei and Masyakin, Anton and Pozdniakov, Sergei and Ivanchenko, Valentina and Shipitsin, Valery},
  title = {OPRM1 rs1799971 Polymorphism Predicts Differential Response to Extended-Release Naltrexone in Alcohol Use Disorder: The Interplay of Genetics and Motivation},
  journal = {Psychopharmacology Bulletin},
  year = {2025},
  doi = {10.64719/pb.4546}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche